Virginia Tech® home

Hourigan Lab

Insert your title here






The Hourigan Lab, led by Christopher Hourigan, DM, DPhil, FRCP,  is focused on bringing precision medicine approaches to the care of patients suffering from the rare, highly fatal, blood cancer Acute Myeloid Leukemia (AML). Based at the Virginia Tech Cancer Research Center in Washington, D.C., the laboratory performs translational research developing high sensitivity genomic tools for the characterization of measurable residual disease (MRD) in patients with AML to predict and prevent relapse. This work includes multiple governmental and private sector partnerships and leadership of the national prospective clinical protocol (‘MEASURE”) to validate and implement AML MRD testing nationwide.

Cancer Research Center – D.C.

Dr. Hourigan leads the Cancer Research Center in Washington, D.C., which brings together basic, translational, and computational researchers of the Fralin Biomedical Research Institute in the our nation’s capital to focus on the shared aim of engineering cancer solutions. Current research efforts involve diverse teams and national and international collaborations, and are motivated by the opportunity to apply world-leading scientific innovation and ingenuity to make measurable progress on the hardest problems

CCRDC logo

Meet the Lab